WO2003068939A3 - Cks1 INHIBITORS - Google Patents

Cks1 INHIBITORS Download PDF

Info

Publication number
WO2003068939A3
WO2003068939A3 PCT/US2003/004550 US0304550W WO03068939A3 WO 2003068939 A3 WO2003068939 A3 WO 2003068939A3 US 0304550 W US0304550 W US 0304550W WO 03068939 A3 WO03068939 A3 WO 03068939A3
Authority
WO
WIPO (PCT)
Prior art keywords
cks1
human
inhibitors
skp2
expression
Prior art date
Application number
PCT/US2003/004550
Other languages
French (fr)
Other versions
WO2003068939A2 (en
Inventor
Annette O Walter
Christoph Reinhard
Anne B Jefferson
Blanche-Marie F Shamoon
Original Assignee
Chiron Corp
Annette O Walter
Christoph Reinhard
Anne B Jefferson
Blanche-Marie F Shamoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Annette O Walter, Christoph Reinhard, Anne B Jefferson, Blanche-Marie F Shamoon filed Critical Chiron Corp
Priority to AU2003215235A priority Critical patent/AU2003215235A1/en
Priority to EP03711050A priority patent/EP1480995A4/en
Priority to CA002474844A priority patent/CA2474844A1/en
Priority to JP2003568054A priority patent/JP2005523280A/en
Priority to US10/504,487 priority patent/US20060089321A1/en
Publication of WO2003068939A2 publication Critical patent/WO2003068939A2/en
Publication of WO2003068939A3 publication Critical patent/WO2003068939A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibitors of human Cks1 and human Skp2, including antisense oligonucleotides, methods, and compositions specific for human Cks1 and human Skp2, are provided. Methods of using the compositions for modulating Cks1 expression and Skp2 expression, and for regulating cell growth, particularly tumor cell growth, are also provided.
PCT/US2003/004550 2002-02-12 2003-02-12 Cks1 INHIBITORS WO2003068939A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003215235A AU2003215235A1 (en) 2002-02-12 2003-02-12 Cks1 INHIBITORS
EP03711050A EP1480995A4 (en) 2002-02-12 2003-02-12 Cks1 INHIBITORS
CA002474844A CA2474844A1 (en) 2002-02-12 2003-02-12 Cks1 inhibitors
JP2003568054A JP2005523280A (en) 2002-02-12 2003-02-12 Cks1 inhibitor
US10/504,487 US20060089321A1 (en) 2002-02-12 2003-02-12 Cks1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35690602P 2002-02-12 2002-02-12
US60/356,906 2002-02-12

Publications (2)

Publication Number Publication Date
WO2003068939A2 WO2003068939A2 (en) 2003-08-21
WO2003068939A3 true WO2003068939A3 (en) 2003-12-31

Family

ID=27734702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004550 WO2003068939A2 (en) 2002-02-12 2003-02-12 Cks1 INHIBITORS

Country Status (5)

Country Link
EP (1) EP1480995A4 (en)
JP (1) JP2005523280A (en)
AU (1) AU2003215235A1 (en)
CA (1) CA2474844A1 (en)
WO (1) WO2003068939A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954896A1 (en) * 2014-06-13 2015-12-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Small molecule inhibitors of the E3 Ligase Skp2 in depression and other diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039527A1 (en) * 1995-06-05 1996-12-12 Mitotix, Inc. Cell-cycle regulatory proteins from human pathogens, and uses related thereto
US6232081B1 (en) * 1997-10-16 2001-05-15 Baylor College Of Medicine Method for the detection of NF-κB regulatory factors
US20030014777A1 (en) * 1997-03-14 2003-01-16 Dirk Inze Method and means for modulating plant cell cycle proteins and their use in plant cell growth control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981702A (en) * 1995-09-21 1999-11-09 Cold Spring Harbor Laboratory Cyclin/CDK associated proteins, and uses related thereto
IL156778A0 (en) * 2001-01-05 2004-02-08 Univ New York Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
CN100578227C (en) * 2001-02-21 2010-01-06 诺华疫苗和诊断公司 TTK in diagnosis and as a therapeutic target in cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039527A1 (en) * 1995-06-05 1996-12-12 Mitotix, Inc. Cell-cycle regulatory proteins from human pathogens, and uses related thereto
US20030014777A1 (en) * 1997-03-14 2003-01-16 Dirk Inze Method and means for modulating plant cell cycle proteins and their use in plant cell growth control
US6232081B1 (en) * 1997-10-16 2001-05-15 Baylor College Of Medicine Method for the detection of NF-κB regulatory factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1480995A4 *

Also Published As

Publication number Publication date
EP1480995A2 (en) 2004-12-01
AU2003215235A1 (en) 2003-09-04
EP1480995A4 (en) 2006-09-13
JP2005523280A (en) 2005-08-04
CA2474844A1 (en) 2003-08-21
AU2003215235A8 (en) 2003-09-04
WO2003068939A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
WO2003093441A3 (en) A method of regulating gene expression
AU2003285172A1 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
WO2004080398A3 (en) 1-amino 1h-imidazoquinolines
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003053340A3 (en) Antisense modulation of connective tissue growth factor expression
MY140767A (en) Compounds, methods and compositions
EP1911757B8 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
AU2003237788A1 (en) Electrode constructs, and related cells and methods
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2004007682A3 (en) Methods and compositions for modulating t helper (th) cell development and function
WO2004053101A3 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
AU2003220115A1 (en) Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
AU2003252025A1 (en) Compounds, compositions, and methods
WO2004003152A3 (en) Sos1 inhibitors
AU2003297700A1 (en) METHODS FOR MODULATING IKKAlpha ACTIVITY
WO2004010956A3 (en) Antisense modulation of lar expression
WO2003062197A3 (en) Nek2 inhibitors
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
WO2003068939A3 (en) Cks1 INHIBITORS
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2003066852A3 (en) Plant growth modulation by drl1 and other proteins of the elongator complex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2474844

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003568054

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003711050

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003711050

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006089321

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10504487

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10504487

Country of ref document: US